Glenmark's expanding US business to surpass Indian specialty revenues in FY12
This article was originally published in Scrip
Executive Summary
Glenmark has received additional FDA approvals in the oral contraceptives segment boosting its portfolio. Management expects that the new approvals will make the US the largest part of Glenmark's business in the 2012 fiscal year, with revenues expected soon to surpass those from its Indian specialty formulation sales.